Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (CLEAR study)

被引：0
|
作者：
Motzer, Robert [1 ]
George, Saby [2 ]
Merchan, Jaime R. [3 ]
Hutson, Thomas E. [4 ,5 ]
Song, Xun [6 ]
Perini, Rodolfo F. [6 ]
Xie, Ran [7 ]
Bapat, Urmi [7 ]
Ebaid, Basant [8 ]
Puente, Javier [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[2] Roswell Park Comprehens Canc Ctr, Dept Med, Buffalo, NY USA
[3] Univ Miami, Dept Med, Sylvester Comprehens Canc Ctr, Miami, FL USA
[4] Baylor Charles A Sammons Canc Ctr, Dept Med Oncol, Texas Oncol, Dallas, TX USA
[5] Texas A&M HSC Coll Med, Bryan, TX USA
[6] Merck & Co Inc, Rahway, NJ 07065 USA
[7] Eisai Inc, Nutley, NJ USA
[8] Eisai Australia Pty Ltd, Melbourne, Vic, Australia
[9] Hosp Clin Univ San Carlos, Dept Med Oncol, Madrid, Spain
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
196
引用
收藏
页码：121 / 122
页数：2
相关论文
共 50 条
  • [31] A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC)
    Hutson, Thomas E.
    Michaelson, M. Dror
    Kuzel, Timothy M.
    Agarwal, Neeraj
    Molina, Ana M.
    Hsieh, James J.
    Vaishampayan, Ulka N.
    Xie, Sharon
    Bapat, Urmi
    Jain, Rohit K.
    Fishman, Mayer N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [32] Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC)
    Panian, Justine
    Zhong, Caiwei
    Choi, Sharon
    Quinn, Roxanne
    Ferrier, Evan
    Saad, Eddy
    Saliby, Renee Maria
    Malvar, Carmel
    Pal, Sumanta Kumar
    Ebrahimi, Hedyeh
    Ben Tran
    Weickhardt, Andrew James
    Lalani, Aly-Khan A.
    Suarez, Cristina
    de Velasco, Guillermo
    Kanesvaran, Ravindran
    Zarba, Martin
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    Mckay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib plus pembrolizumab (L plus P) in the phase 3 CLEAR trial.
    Keizman, Daniel
    Bedke, Jens
    Staehler, Michael D.
    Matveev, Vsevolod B.
    George, Saby
    Hutson, Thomas E.
    Vaishampayan, Ulka N.
    Merchan, Jaime R.
    Eto, Masatoshi
    Rha, Sun Young
    Waddell, Tom
    Sabbatini, Roberto
    Barthelemy, Philippe
    Burgents, Joseph E.
    Ren, Min
    Brown, Ian
    Saal, Hakim
    Choueiri, Toni K.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 531 - 531
  • [34] KEYTRUDA® (Pembrolizumab) plus KISPLYX® (Lenvatinib) - First-Line Treatment of Patients with advanced Renal Cell Carcinoma
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 70 - 70
  • [35] Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)
    Grunwald, Viktor
    Powles, Thomas
    Eto, Masatoshi
    Kopyltsov, Evgeny
    Rha, Sun Young
    Porta, Camillo
    Motzer, Robert
    Hutson, Thomas E.
    Mendez-Vidal, Maria Jose
    Hong, Sung-Hoo
    Winquist, Eric
    Goh, Jeffrey C.
    Maroto, Pablo
    Buchler, Tomas
    Takagi, Toshio
    Burgents, Joseph E.
    Perini, Rodolfo
    He, Cixin
    Okpara, Chinyere E.
    McKenzie, Jodi
    Choueiri, Toni K.
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [36] Lenvatinib plus Pembrolizumab as first-line treatment in patients with advanced renal cell carcinoma (aRCC) - real world data from a retrospective multi- center analysis
    Stelmach, Ramona
    Schlack, Katrin
    Muhle, Clemens
    Darr, Christopher
    Neuberger, Stephanie
    Reichert, Mathias
    Rehlinghaus, Marc
    Flegar, Luka
    Zengerling, Friedemann
    Casuscelli, Jozefina
    Cox, Alexander
    Nestler, Tim
    Egenolf, Timo
    Brehmer, Bernhard
    Vallet, Sonia
    Ivanyi, Philipp
    Neuberger, Manuel
    Paffenholz, Pia
    Grunwald, Viktor
    Zschabitz, Stefanie
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 88 - 88
  • [37] A Phase IB/II Trial of Lenvatinib plus Pembrolizumab in Patients With Renal Cell Carcinoma
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Taylor, Matthew
    Dutcus, Corina
    Shumaker, Robert
    Schmidt, Emmett
    Stepan, Daniel E.
    Li, Di
    Young, Louise
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 153 - 153
  • [38] Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jaime R.
    Goh, Jeffrey C.
    Kapoor, Anil
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Rodriguez-Lopez, Karla
    He, Cixin S.
    Okpara, Chinyere
    McKenzie, Jodi
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).
    Gruenwald, Viktor
    Winquist, Eric
    Peer, Avivit
    Schmidinger, Manuela
    Procopio, Giuseppe
    Barthelemy, Philippe
    Lee, Jae-Lyun
    Rudman, Sarah
    Kadambi, Ananth
    Pandey, Anuja
    Neupane, Binod
    Fahrbach, Kyle
    Purushotham, Sneha
    Jones, Michael
    Egodage, Sonya
    Kashyap, Ananth
    Hauck, Wendy
    Pan, Janice
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 482 - 482
  • [40] NETWORK META-ANALYSIS (NMA) TO ASSESS COMPARATIVE EFFICACY OF LENVATINIB PLUS PEMBROLIZUMAB COMPARED WITH OTHER FIRST-LINE TREATMENTS FOR MANAGEMENT OF ADVANCED RENAL CELL CARCINOMA (ARCC)
    Kadambi, A.
    Pandey, A.
    Neupane, B.
    Fahrbach, K.
    Purushotham, S.
    Jones, M.
    Egodage, S.
    Kashyap, A.
    Pan, J.
    VALUE IN HEALTH, 2022, 25 (07) : S310 - S310
12345